Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF

  80% confidence

• HARMONi-A represents the first statistically significant overall survival benefit achieved in a Phase III study by an ivonescimab-containing regimen

  80% confidence

• Based on the results of the multiregional HARMONi study, we plan to submit a Biologics License Application (BLA)

  80% confidence

• Summit intends to open clinical trial sites in the United States for the Phase III study in CRC by the end of 2025

  80% confidence

• Over 3,000 patients have been treated with ivonescimab in clinical studies globally, and over 40,000 patients when considering those treated in a commercial setting in China

  80% confidence

• Ivonescimab has a half-life of 6 to 7 days after the first dose increasing to approximately 10 days at steady state dosing

  80% confidence

• In China, over 40,000 patients have been treated with ivonescimab in either a clinical or commercial setting

  80% confidence

• This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials

  80% confidence

Citado nestas reportagens da Via News

• Global Precision Oncology Race Intensifies as Biotech Firms Across Three Continents Target Regulatory Milestones →